MariMed Restructures Preferred Stock and Secures New Financing

MariMed ( (MRMD) ) has issued an update.

On February 24, 2026, MariMed Inc. and major investor Navy Capital Green International restructured a looming obligation tied to legacy Series B preferred shares that would have required a cash payment of about $14.2 million in 2026. The deal cancelled the existing Series B preferred stock and extinguished that obligation, easing near-term balance sheet pressure while preserving Navy’s economic stake.

In exchange, MariMed issued Navy $8 million in new promissory notes maturing in 2028 and 2031 and 26.9 million shares of a new, non-voting Series B Convertible Preferred Stock with a $6.725 million aggregate liquidation preference. The new preferred shares carry senior dividend and liquidation rights over common stock and feature multiple conversion and cash-settlement options through 2031, potentially diluting common shareholders but providing the company with greater flexibility in managing future cash outflows and capital structure.

On February 26, 2026, the company filed a Second Amended and Restated Certificate of Designation in Delaware, formally establishing the rights and preferences of the new Series B Preferred Stock. The issuance to Navy was conducted as a private placement under U.S. securities law exemptions, signaling continued reliance on institutional capital rather than public equity markets for financing.

The most recent analyst rating on (MRMD) stock is a Hold with a $0.09 price target. To see the full list of analyst forecasts on MariMed stock, see the MRMD Stock Forecast page.

Spark’s Take on MRMD Stock

According to Spark, TipRanks’ AI Analyst, MRMD is a Neutral.

MariMed’s overall stock score reflects significant financial challenges, including negative profit margins and high leverage. While there is some positive momentum in technical indicators, the valuation remains unattractive due to ongoing losses. The earnings call provided mixed insights, with growth in certain areas but also notable challenges.

To see Spark’s full report on MRMD stock, click here.

More about MariMed

MariMed Inc. is a U.S. cannabis company that develops, owns, and manages cannabis cultivation, production, and dispensary facilities, and markets branded cannabis products. The company focuses on regulated medical and adult-use cannabis markets, using complex financing and equity structures to fund growth and manage its capital obligations.

Average Trading Volume: 952,701

Technical Sentiment Signal: Sell

Current Market Cap: $33.5M

Find detailed analytics on MRMD stock on TipRanks’ Stock Analysis page.